{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-025017","form_type":"8-K","ticker":"HRGN","cik":"0001563665","company_name":"Harvard Apparatus Regenerative Technology, Inc.","filed_at":"2023-07-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.338078+00:00","generated_at":"2026-06-13T05:35:52.909769+00:00","sec_items":["5.03","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"Harvard Apparatus Regenerative (fka Biostage) trades under HRGN; FDA clears 10-patient phase 1 esophageal study","bullets":["Name changed from Biostage to Harvard Apparatus Regenerative Technology; new ticker HRGN on OTCQB effective July 20, 2023.","FDA approved a 10-patient phase 1 study for esophageal implant; enrollment opened.","Company plans to launch anti-aging business in China; expects it to be cash flow positive in fiscal 2023.","Launched new website www.hregen.com to highlight regenerative technology and anti-aging strategy."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-025017","json":"https://secwatch.observer/filing/0001493152-23-025017.json","markdown":"https://secwatch.observer/filing/0001493152-23-025017.md","text":"https://secwatch.observer/filing/0001493152-23-025017.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1563665/000149315223025017/0001493152-23-025017-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1563665/000149315223025017/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T05:35:52.909769+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1ff472590c16e571127767ecb54bf160965a2622","claim":"Harvard Apparatus Regenerative Technology, Inc.: Amended and restated Bylaws solely to reflect the name change to Harvard Apparatus Regenerative Technology, Inc (effective 2023-07-20).","evidence_excerpt":"The Company also amended and restated its Amended and Restated Bylaws, solely to reflect the name change (as amended, the “Third Amended and Restated Bylaws”). The Certificate of Amendment and the Third Amended and Restated Bylaws each became effective on July 20, 2023.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1563665/000149315223025017/0001493152-23-025017-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"bylaw amendment"},{"label":"Effective","value":"2023-07-20"}],"fact_type":"governance_change"},{"claim_id":"7f10500a29644da610df89f335dd0258d2fcbbca","claim":"Harvard Apparatus Regenerative Technology, Inc.: Amended Certificate of Incorporation to change company name from Biostage, Inc. to Harvard Apparatus Regenerative Technology, Inc (effective 2023-07-20).","evidence_excerpt":"Harvard Apparatus Regenerative Technology, Inc. (the “Company”) filed an amendment (the “Certificate of Amendment”) to its Amended and Restated Certificate of Incorporation (the “Certificate of Incorporation”) with the Secretary of State for the State of Delaware to change its name from Biostage, Inc. to Harvard Apparatus Regenerative Technology, Inc. The Company also amended and restated its Amended and Restated Bylaws, solely to reflect the name change (as amended, the “Third Amended and Restated Bylaws”). The Certificate of Amendment and the Third Amended and Restated Bylaws each became effective on July 20, 2023.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1563665/000149315223025017/0001493152-23-025017-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2023-07-20"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}